|
|
||||||||
Original Research |
1 Department of Radiology, Wake Forest University Health Sciences, Medical
Center Blvd., Winston-Salem, NC 27157-1008.
2 Department of Urology, Wake Forest University Health Sciences, Winston-Salem,
NC.
3 Present address: Department of Urology, Vanderbilt University School of
Medicine, Nashville, TN.
OBJECTIVE. A single institution's experience with CT-guided percutaneous radiofrequency ablation of biopsy-proven renal cell carcinomas (RCCs) was studied to determine the disease-free survival and complication rate.
MATERIALS AND METHODS. Data from 125 RCCs in 104 patients treated with curative intent was reviewed. Radiofrequency ablation treatments were performed using conscious sedation and local anesthesia. Patients were followed with contrast-enhanced CT or MRI. Tumor control was defined as the absence of contrast enhancement in the tumor on CT or MRI.
RESULTS. Tumor size ranged from 0.6 to 8.8 cm (mean, 2.7 cm; SD, 1.5 cm). Of the 125 treated tumors, 116 (93%) were completely ablated (109 in a single ablation session, seven after a second ablation session) with a mean follow-up interval of 13.8 months. All 95 RCCs smaller than 3.7 cm were completely ablated, and 21 (70%) of 30 larger tumors were completely ablated, with nine showing evidence of residual viable tumor on follow-up scans. Tumor size smaller than 3.7 cm was significantly associated with achieving complete tumor eradication (p < 0.001). With each 1-cm increase in tumor diameter over 3.6 cm, the likelihood of tumor-free survival decreased by a factor of 2.19 (p < 0.001). There were 8 (8%) complications, none of which resulted in long-term morbidity.
CONCLUSION. CT-guided percutaneous radiofrequency ablation is a safe method to treat small RCCs. This study indicates that radiofrequency ablation can reliably eradicate RCCs smaller than 3.7 cm. Treatment of larger RCCs will result in an increased risk of residual RCC.
Keywords: interventional radiology radiofrequency ablation renal neoplasms
![]()
CiteULike
Complore
Connotea
Del.icio.us
Digg
Reddit
Technorati What's this?
This article has been cited by other articles:
![]() |
M. F. Meloni, M. Bertolotto, C. Alberzoni, S. Lazzaroni, C. Filice, T. Livraghi, and G. Ferraioli Follow-Up After Percutaneous Radiofrequency Ablation of Renal Cell Carcinoma: Contrast-Enhanced Sonography Versus Contrast-Enhanced CT or MRI Am. J. Roentgenol., October 1, 2008; 191(4): 1233 - 1238. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. A O'Keeffe, S. McNally, and M. T Keogan Investigating painless haematuria BMJ, July 9, 2008; 337(jul09_3): a260 - a260. [Full Text] |
||||
![]() |
P. V. Pandharipande, D. A. Gervais, P. R. Mueller, C. Hur, and G. S. Gazelle Radiofrequency Ablation versus Nephron-sparing Surgery for Small Unilateral Renal Cell Carcinoma: Cost-effectiveness Analysis Radiology, July 1, 2008; 248(1): 169 - 178. [Abstract] [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |